AHRMM

Articles

Analytics & Research, Benchmarking, Cost, Quality and Outcomes (CQO) Movement, Disaster/Outbreak Preparedness, Physician Preference Items (PPI), Performance Metrics

Leading Practice: Reduction or Elimination in Hospital Acquired NPU - Terrebonne General Medical Center

AHRMM is developing a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a Cost, Quality, and Outcomes (CQO) perspective. The following Hospital Acquired Nosocomial Pressure Ulcers (NPU) leading practice was submitted by:

Benchmarking, Clinical Resource Management (CRM), Cost, Quality and Outcomes (CQO) Movement, Disaster/Outbreak Preparedness, Physician Preference Items (PPI), Value Analysis

Leading Practice: Reduction or Elimination of CAUTI - Blue.Point Supply Chain Solutions

AHRMM is offering a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a Cost, Quality, and Outcomes (CQO) perspective. The following Catheter Acquired Urinary Tract Infection (CAUTI) leading practice was submitted by:

Blue.Point Supply Chain Solutions, Andover, MA

Products and Services Contracting, Cost Management, Cost, Quality and Outcomes (CQO) Movement, Disaster/Outbreak Preparedness, Suppliers, Procurement

Leading Practice: Reduction or Elimination of CAUTI - Nexera, Inc.

AHRMM is offering a repository for leading and proven supply chain practices, case studies, and toolkits that are developed from a Cost, Quality, and Outcomes (CQO) perspective. The following Catheter Acquired Urinary Tract Infections (CAUTI) leading practice was submitted by:

Nexera, Inc., New York, NY

Products and Services Contracting, Data Standards, Distribution, Regulations and Regulatory Advocacy, Unique Device Identifier (UDI), Logistics

FDA Releases Proposed Rule on Unique Device System for Medical Devices

The FDA UDI ruling has finally arrived - the proposed rule has published. Please see the FDA website (www.fda.gov/udi) for a link to the proposed regulation. Highlights include a 120 day comment period to begin shortly, 6 months later a final ruling that will begin with Class III devices within 2 years, possibly sooner.

Below is the FDA press release: